Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 16924
Sealed predictions
- PNISR in dopamine neurons, braak-0.21 (p 0.581) → +0.60 (p 0.089)receipt 16933
Swarm cases
receipt 16933: PNISR in dopamine neurons, braak
- power
- full sample +0.16 (p 0.526, n 18), 95% CI -0.33 to +0.58. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.16 (p 0.526, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.34 (p 0.167, n 18). could be the mix.
- skeptic
- leave-one-out range +0.05 to +0.29, sign flips 0; without severely affected donors +0.16 (p 0.526, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.64 (p 0.0045, n 18) vs +0.16 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PNISR in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up PNISR · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.60 p 0.033 (needs p < 1.4e-4)
Receipts
loading the receipts